{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:52:22Z","timestamp":1777963942999,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In early-stage endometrial cancer (EC), the treatment of aggressive histological subtypes (endometrioid carcinoma grade 3, serous carcinoma, clear-cell carcinoma, undifferentiated carcinoma, mixed carcinoma, and carcinosarcoma) is controversial. We aimed to investigate the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IC and stage IIC EC according to the 2023 classification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively identified patients with FIGO 2023 stage IC, IIC-intermediate risk (IIC-I), and IIC-high risk (IIC-H) EC who underwent adjuvant therapy or observation after surgery at eight medical institutions from 2004 to 2023. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan\u2013Meier estimates and univariate and multivariate analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The PFS and OS were significantly worse in patients with FIGO 2023 stage IIC-H EC than in those with FIGO 2023 stage IIC-I EC (PFS: p\u2009=\u20090.008 and OS: p\u2009=\u20090.006). According to the FIGO 2023 stage IIC-H classification, lymphadenectomy and chemotherapy resulted in better prognoses regarding both PFS and OS (p\u2009&lt;\u20090.001 for both) than other treatments. Our findings suggest that lymphadenectomy and chemotherapy effectively reduced vaginal stump and lymph node metastases in FIGO 2023 stage IIC-H EC (p\u2009&lt;\u20090.001 and p\u2009=\u20090.008, respectively). Furthermore, in the multivariate analysis, not undergoing lymphadenectomy or chemotherapy were independent predictors of recurrence and poor prognoses in patients with FIGO 2023 stage IIC-H EC (p\u2009&lt;\u20090.001 and p\u2009=\u20090.031, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Lymphadenectomy and chemotherapy resulted in better prognoses regarding both recurrence and survival in patients with FIGO 2023 stage IIC high-risk EC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-024-02647-4","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T02:39:35Z","timestamp":1731119975000},"page":"144-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphadenectomy and chemotherapy are effective treatments for patients with 2023 international federation of gynecology and obstetrics stage IIC-high risk endometrial cancer in Japan"],"prefix":"10.1007","volume":"30","author":[{"given":"Yoshinori","family":"Tani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-5258","authenticated-orcid":false,"given":"Keiichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masae","family":"Yorimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Itou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Masuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"2647_CR2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e76","author":"S Shigeta","year":"2017","unstructured":"Shigeta S, Nagase S, Mikami M et al (2017) Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2017.28.e76","journal-title":"J Gynecol Oncol"},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C et al (2023) FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 162:383\u2013394. https:\/\/doi.org\/10.1002\/ijgo.14923","journal-title":"Int J Gynaecol Obstet"},{"key":"2647_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0140-6736(08)61766-3","volume":"373","author":"H Kitchener","year":"2009","unstructured":"Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125\u2013136. https:\/\/doi.org\/10.1016\/s0140-6736(08)61766-3","journal-title":"Lancet"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/jnci\/djn397","volume":"100","author":"P Benedetti Panici","year":"2008","unstructured":"Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707\u20131716. https:\/\/doi.org\/10.1093\/jnci\/djn397","journal-title":"J Natl Cancer Inst"},{"key":"2647_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/s0140-6736(09)62002-x","volume":"375","author":"Y Todo","year":"2010","unstructured":"Todo Y, Kato H, Kaneuchi M et al (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375:1165\u20131172. https:\/\/doi.org\/10.1016\/s0140-6736(09)62002-x","journal-title":"Lancet"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ygyno.2019.09.017","volume":"156","author":"PA Chodavadia","year":"2020","unstructured":"Chodavadia PA, Jacobs CD, Wang F et al (2020) Off-study utilization of experimental therapies: analysis of GOG249-eligible cohorts using real world data. Gynecol Oncol 156:154\u2013161. https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.017","journal-title":"Gynecol Oncol"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer SM, Powell ME, Mileshkin L et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295\u2013309. https:\/\/doi.org\/10.1016\/s1470-2045(18)30079-2","journal-title":"Lancet Oncol"},{"key":"2647_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s1470-2045(19)30395-x","volume":"20","author":"SM de Boer","year":"2019","unstructured":"de Boer SM, Powell ME, Mileshkin L et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273\u20131285. https:\/\/doi.org\/10.1016\/s1470-2045(19)30395-x","journal-title":"Lancet Oncol"},{"key":"2647_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"21","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R et al (2023) Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21:181\u2013209. https:\/\/doi.org\/10.6004\/jnccn.2023.0006","journal-title":"J Natl Compr Canc Netw"},{"key":"2647_CR11","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e33","volume":"35","author":"YY Lee","year":"2024","unstructured":"Lee YY, Lai YL, Kim MS et al (2024) Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan. J Gynecol Oncol 35:e33. https:\/\/doi.org\/10.3802\/jgo.2024.35.e33","journal-title":"J Gynecol Oncol"},{"key":"2647_CR12","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e89","author":"U Akgor","year":"2024","unstructured":"Akgor U (2024) Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2024.35.e89","journal-title":"J Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02647-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T06:05:06Z","timestamp":1735970706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02647-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02647-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Okayama University (ethics number: 2311-023), with an exemption for patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}